CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia

Patients with chemo-refractory acute myeloid leukemia (AML) have a dismal prognosis. Chimeric antigen receptor T (CART) cell therapy has produced exciting results in CD19+ malignancies and may overcome many of the limitations of conventional leukemia therapies. We developed CART cells to target CD33...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Leukemia
Auteurs principaux: Kenderian, SS, Ruella, M, Shestova, O, Klichinsky, M, Aikawa, V, Morrissette, JJD, Scholler, J, Song, D, Porter, DL, Carroll, M, June, CH, Gill, S
Format: Artigo
Langue:Inglês
Publié: 2015
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4644600/
https://ncbi.nlm.nih.gov/pubmed/25721896
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2015.52
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires